Novo Nordisk, the Wegovy maker, received a formal reprimand for failing to disclose numerous payments to UK health organizations.
These undisclosed payments, spanning several years, involved various groups including pharmacies and charities, significantly impacting public trust.
The pharmaceutical watchdog found numerous breaches of industry code, revealing a lack of transparency and governance within Novo Nordisk.
Despite internal reviews, further unreported payments were discovered, leading to a formal rebuke and raising concerns about industry practices.
